Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 0.00% is 100% above its 5-year average of -2120.38%, near the high end of its 5-year range (-417794000.00%–0.00%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
-2120.38%
NET PROFIT MARGIN AVG 10Y
-1404.99%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
+100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 644 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Inhibikase Therapeutics, Inc.
Market Cap
$262.09M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-2120.38%
Market Cap
$262.66M
Net Profit Margin
-249.94%
TTM Avg
-1079.05%
3Y Avg
-1080.63%
5Y Avg
-787.30%
Market Cap
$262.97M
Net Profit Margin
-6388.20%
TTM Avg
0.00%
3Y Avg
-1230.00%
5Y Avg
-820.00%
Market Cap
$258.73M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-2265.94%
5Y Avg
-2185.44%
Market Cap
$264.72M
Net Profit Margin
-43.70%
TTM Avg
-35.13%
3Y Avg
-15.36%
5Y Avg
-13.33%
Market Cap
$266.17M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$256.22M
Net Profit Margin
-8.78%
TTM Avg
-964.82%
3Y Avg
-2640.79%
5Y Avg
-1760.53%
Market Cap
$255.48M
Net Profit Margin
-3.14%
TTM Avg
-28.33%
3Y Avg
-34.54%
5Y Avg
-25.62%
Market Cap
$266.79M
Net Profit Margin
-10994.73%
TTM Avg
-520.92%
3Y Avg
-360.66%
5Y Avg
-288.77%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | $262.09M | 0.00% | 0.00% | 0.00% | -2120.38% |
| AC Immune S.A. (ACIU)vs › | $262.66M | -249.94% | -1079.05% | -1080.63% | -787.30% |
| Palisade Bio, Inc. (PALI)vs › | $262.97M | -6388.20% | 0.00% | -1230.00% | -820.00% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $258.73M | 0.00% | 0.00% | -2265.94% | -2185.44% |
| OraSure Technologies, Inc. (OSUR)vs › | $264.72M | -43.70% | -35.13% | -15.36% | -13.33% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $266.17M | 0.00% | 0.00% | 0.00% | 0.00% |
| Century Therapeutics, Inc. (IPSC)vs › | $256.22M | -8.78% | -964.82% | -2640.79% | -1760.53% |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.48M | -3.14% | -28.33% | -34.54% | -25.62% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $266.79M | -10994.73% | -520.92% | -360.66% | -288.77% |
| Invivyd, Inc. (IVVD)vs › | $246.29M | -183.90% | -383.83% | -191.92% | -127.94% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | -417794000.00% |
| 2023-09-30 | -5775.11% |
| 2023-06-30 | -4963.46% |
| 2023-03-31 | -6940.14% |
| 2022-12-31 | -6731.67% |
| 2022-09-30 | -61645.36% |
| 2022-06-30 | -70817.14% |
| 2022-03-31 | -10081.47% |
| 2021-12-31 | -259342.54% |
| 2021-09-30 | -1361.26% |
| 2021-06-30 | -193.40% |
| 2021-03-31 | -187.40% |
| 2020-12-31 | -708.85% |
| 2020-09-30 | -1779.72% |
| 2020-06-30 | -192.12% |
| 2020-03-31 | -202.17% |
| 2019-12-31 | -178.97% |
| 2019-09-30 | -974.37% |
| 2019-06-30 | -1404.30% |
| 2019-03-31 | -293.75% |
| 2018-12-31 | -94.02% |
| 2018-03-31 | -18.08% |
| 2017-12-31 | 5.60% |
| 2017-03-31 | -75.05% |
